Patients with atrial fibrillation are often elderly and have multiple comorbidities, leading to a high risk of cardiovascular events1,2,3 despite the use of oral anticoagulants, whether with the vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs).